Stockscreener 앱 받기
13.50
1.75%
-0.24
시간 외 거래:
13.42
-0.08
-0.59%
전일 마감가:
$13.74
열려 있는:
$13.75
하루 거래량:
11.61M
Relative Volume:
1.14
시가총액:
$15.54B
수익:
$14.29B
순이익/손실:
$-3.51B
주가수익비율:
-4.5603
EPS:
-2.9603
순현금흐름:
$1.85B
1주 성능:
-2.17%
1개월 성능:
-15.52%
6개월 성능:
+36.36%
1년 성능:
+43.31%
1일 변동 폭
$13.12
$13.88
1주일 범위
$13.12
$13.97
52주 변동 폭
$6.85
$16.47
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.50 | 15.82B | 14.29B | -3.51B | 1.85B | -2.9603 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris sets revenue growth targets through 2030 - Investing.com
Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - PR Newswire
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey
Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF
Henrietta Lacks family settles lawsuit against Viatris over use of her cells - WJLA
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves - Yahoo Finance
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey
Assessing Viatris (VTRS) Valuation After Recent Share Price Pullback - simplywall.st
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit - marketscreener.com
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Novo, Mylan Seek Judgment on Key Wegovy Patent Before Trial - Bloomberg Law News
Viatris resolves case over use of woman’s cancer cells (VTRS) - Seeking Alpha
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Viatris (VTRS) CCO granted RSUs, settles prior units and tax withholdings - Stock Titan
Viatris (VTRS) CFO adds 86,017 RSUs and withholds shares for taxes - Stock Titan
Viatris (VTRS) director adds 26K shares via RSU vesting and grant - Stock Titan
Viatris (VTRS) executive Enrietti exercises RSUs, withholds shares for taxes - Stock Titan
Viatris (VTRS) director Mark W. Parrish reports RSU vesting and new equity award - Stock Titan
Viatris (VTRS) executive settles RSUs, receives new 56,727-unit award - Stock Titan
Viatris (VTRS) CEO boosts equity stake with RSU vesting and new award - Stock Titan
[Form 4] Viatris Inc Insider Trading Activity - Stock Titan
VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan
Viatris (VTRS) director Kilts exercises RSUs and receives new stock grant - Stock Titan
Viatris (VTRS) director settles RSUs into shares and receives 15,890-unit grant - Stock Titan
Viatris (VTRS) director exercises RSUs and receives new stock award - Stock Titan
Viatris (VTRS) director acquires shares and new RSUs via awards - Stock Titan
Viatris (VTRS) director reports 684 common shares via trusts - Stock Titan
Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results? - Bitget
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc.: - marketscreener.com
Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Viatris tops forecasts as earnings and revenue beat expectations - MSN
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - Sahm
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.39%
0.77%
자본화:
|
볼륨(24시간):